Tweets
Come visit @rheumnow where #ACR24 #RheumEducation is distilled and disseminated. @uptoTate https://t.co/vzMeRL8307
TheDaoIndex @KDAO2011 ( View Tweet )
1 year 2 months ago
Coming from somewhere where biosimilars are SOC for many years, I just find it wild how things are biosimilar wise in the US. Reflected by so many abstracts, including lots of oral presentations, essentially on showing biosimilars work. #ACR24 @RheumNow
Richard Conway @RichardPAConway ( View Tweet )
1 year 2 months ago
What is my risk of developing SLE?
Abstract 0843 highlights a predictive model that accurately classifies SLE risk using genetics, lifestyle, and environmental factors. Model 3 (genetics + environment + lifestyle) performed the best compared to models 1 and 2.
@RheumNow #ACR24 https://t.co/sk9oG0OY3W
Akhil Sood MD @AkhilSoodMD ( View Tweet )
1 year 2 months ago
Challener et al. TriNetX study. 32,000 patients. SGLT2i reduce need for gout visits (HR 0.94) ULT initiation (HR 0.69) and colchicine (HR 0.82). I worry about the discordant rates, ULT initiation much lower. @RheumNow #ACR24 Abstr#0848 https://t.co/VTKHMmDEKV https://t.co/C2opiDmBXx
Links:
Richard Conway @RichardPAConway ( View Tweet )
1 year 2 months ago
Should we screen new #PMR pts for #LVV?
Pts with PMR had lower risk of aortic complications vs #GCA & similar risk as gen pop
BUT if they developed GCA later, the risk was same as those with new GCA
➡️Screening recommended in new GCA but not PMR pts
Ab0859 #ACR24 @RheumNow https://t.co/HsHPGlt5A9
Links:
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 2 months ago
@abdelhamed012 @RheumNow Same https://t.co/uScez6UwBp
Richard Conway @RichardPAConway ( View Tweet )
1 year 2 months ago
Race of b/tsDMARDs in RA, the “JAK-pot” study.
JAKi and TNFi with more rapid early improvement in CDIA, HAQ, and pain compared to ABA or IL-6 inhibitors…..although effects blunted after adjusting for patient and RA characteristics
#ACR24 @RheumNow ABST#0501 https://t.co/8M4wX3LAbW
Jiha Lee @JihaRheum ( View Tweet )
1 year 2 months ago
🤵♂️Results from BACHELOR
➡️34 PMR pts
➡️18 BARI, 16 PBO
➡️Primary endpoint: CRP PMR-AS≤10 w/o oral GC rescue from W0 to 12
78% BARI pts reached primary endpoint vs 13% PBO
No new safety signals
BARI 4mg 12W, then 2mg 12W➡️36W low disease activity in PMR
Ab0858 #ACR24 @RheumNow
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 2 months ago
How does #cardiovascular risk vary with #ACPA & #biologics in #RA?
⬆️BMI assoc with ⬆️MACE risk in ACPA+ pts
In ACPA- pts, BMI inversely assoc with MACE risk among pts on biologics
Further evidence to consider ACPA, BMI & MACE as part of RA management
Ab0870 #ACR24 @RheumNow https://t.co/UkkC146DWS
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 2 months ago
JAKs in PMR? "BACHELOR" study randomized 34pts to BARI vs PLBO
Despite small sample, significant benefit at 12 wks (CRP PMR-AS < 10) for bari (78%) vs. PLBO (13%)
Useful, but not for getting regulatory approval. Should have gone straight to phase 3!
#ACR24 @RheumNow Abstr#0858 https://t.co/mmMs6c3AYC
Links:
Mike Putman @EBRheum ( View Tweet )
1 year 2 months ago
📸 #ACR24 Selfie Highlights!
1️⃣ @Sethsaidso and Jack Cush, MD from @RheumNow – a dynamic duo in rheumatology!
2️⃣ @Sethsaidso and @KenSaag, MD, MSc – renowned rheumatologist and clinical investigator from UAB.
3️⃣ @Sethsaidso and @Dr_ValenzuelaMD – exceptional rheumatologist from… https://t.co/9AseHvXE1V https://t.co/Vr5rxkmCqH
Links:
CreakyJoints.org @CreakyJoints ( View Tweet )
1 year 2 months ago
How early is early?
Data from SPACE cohort included 548 pts with CBP (<2y duration) and different SpA features followed over 2years.
-At the end of 2 years, 39% pts were dx with axSpA.
-Median time to dx: 35 months.
-HLAB27+, sacroilitis on MR and peripheral arthritis were the… https://t.co/AYtJCp8yno https://t.co/VL7KSrpvp9
Links:
Adela Castro @AdelaCastro222 ( View Tweet )
1 year 2 months ago
